Table 3. Changes of PD-related markers in serum.
| Blood test | Experimental group, n = 30 | Control group, n = 30 | Unadjusted effect (95%CI) | Unadjusted P-value | Adjusted effect (95%CI) | Adjusted P-value |
|---|---|---|---|---|---|---|
| Baseline | ||||||
| PGF2α ↓ | 731.55±149.37 | 732.42±154.22 | -0.86 (-79.33, 77.60) | .98 | -3.13, (-84.40, 78.14) | .94 |
| OT ↓ | 155.38±28.21 | 165.32±29.58 | -9.94 (-24.88, 5.00) | .19 | -11.06 (-26.48, 4.37) | .16 |
| vWF ↓ | 2.72±0.89 | 2.69±0.74 | 0.04 (-0.39, 0.46) | .87 | 0.00 (-0.43, 0.43) | .99 |
| β-EP ↑ | 206.27±68.12 | 226.60±81.65 | -20.33 (-59.19, 18.53) | .30 | -19.71 (-59.98, 20.56) | .33 |
| PGE2 ↓ | 591.12±243.16 | 549.04±260.43 | 42.08 (-88.13, 172.30) | .52 | 39.22 (-95.68, 174.13) | .56 |
| 3 months | ||||||
| PGF2α ↓ | 311.88±110.53 | 298.74±81.86 | 13.14 (-37.13, 63.40) | .60 | 13.63 (-38.46, 65.72) | .60 |
| OT ↓ | 65.32±25.34 | 61.01±20.29 | 4.31 (-7.56, 16.17) | .47 | 4.36 (-7.93, 16.66) | .48 |
| vWF ↓ | 1.13±0.34 | 1.01±0.37 | 0.13 (-0.06, 0.31) | .17 | 0.13 (-0.06, 0.32) | .18 |
| β-EP ↑ | 412.17±70.74 | 431.39±125.31 | -19.22 (-71.80, 32.37) | .47 | -17.19 (-71.64, 37.26) | .53 |
| PGE2 ↓ | 332.11±211.39 | 454.26±213.45 | -122.14(-231.93, -12.35) | .03 | -99.57 (-210.28, 11.13) | .08 |